Benralizumab as a Steroid-Sparing Treatment Option in Eosinophilic Granulomatosis with Polyangiitis.
Vamsi P Guntur, Laurie A Manka, Joshua L Denson...
https://pubmed.ncbi.nlm.nih.gov/33065367/Actively Recruiting
Led by European EGPA Study Group · Updated on 2026-09-11
100
Participants Needed
1
Research Sites
52 weeks
Total Duration
Researchers are evaluating the long-term real-world safety and effectiveness of benralizumab in adult patients diagnosed with eosinophilic granulomatosis with polyangiitis EGPA. This observational study includes patients treated at specialized EGPA centers within the European EGPA Study Group. The study involves adults meeting specific diagnostic criteria who receive benralizumab and have at least 3 months of follow-up data available. Participants receive benralizumab at a dose of 30 mg every 4 weeks. The study collects clinical, laboratory, lung function, treatment, relapse, and safety information from medical records at baseline and at 3, 6, 12, and 24 months after starting treatment. The study also compares outcomes between patients receiving benralizumab as first-line biologic therapy and those previously treated with mepolizumab. Dosage changes and adverse events will be recorded during follow-up. During the study, researchers review data on disease activity, lung function changes, relapses, treatment persistence, corticosteroid use, and adverse events. Data are collected through standardized electronic reports from the patients medical charts. The total follow-up period is up to 24 months, with assessments at multiple scheduled intervals. All information is anonymized and stored centrally to ensure patient confidentiality.
CONDITIONS
Benralizumab Effectiveness in EGPA
G
Giacomo Emmi, MD/PhD
I
Irene Mattioli, PharmD/PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
European EGPA Study Group
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote) to confirm eligibility and collect consent
Duration - Up to 24 months
Researchers collect clinical, laboratory, lung function, treatment, relapse, and safety data from medical records at the start of benralizumab treatment and at 3, 6, 12, and 24 months of follow-up.
Data collected during routine care visits
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Vamsi P Guntur, Laurie A Manka, Joshua L Denson...
https://pubmed.ncbi.nlm.nih.gov/33065367/Adrien Cottu, Matthieu Groh, Charlene Desaintjean...
https://pubmed.ncbi.nlm.nih.gov/37550002/Santi Nolasco, Andrea Portacci, Raffaele Campisi...
https://pubmed.ncbi.nlm.nih.gov/37457743/Alessandra Bettiol, Maria Letizia Urban, Lorenzo Dagna...
https://pubmed.ncbi.nlm.nih.gov/34347947/Paul A Lyons, James E Peters, Federico Alberici...
https://pubmed.ncbi.nlm.nih.gov/31719529/Alessandra Bettiol, Maria Letizia Urban, Federica Bello...
https://pubmed.ncbi.nlm.nih.gov/35850947/Michael E Wechsler, Parameswaran Nair, Benjamin Terrier...
https://pubmed.ncbi.nlm.nih.gov/38393328/Bernhard Hellmich, Beatriz Sanchez-Alamo, Jan H Schirmer...
https://pubmed.ncbi.nlm.nih.gov/36927642/Irene Mattioli, Maria Letizia Urban, Roberto Padoan...
https://pubmed.ncbi.nlm.nih.gov/40147217/Alice Canzian, Nils Venhoff, Maria Letizia Urban...
https://pubmed.ncbi.nlm.nih.gov/33001543/European EGPA Study Group
Lead Sponsor